Close this search box.

LYPHE Group announces revolutionary medical cannabis advisory board

The UK’s leading provider of medical cannabis, LYPHE Group, has today announced its new Medical Advisory Board. 

LYPHE Group’s new Medical Advisory Board is set to revolutionise the medical cannabis market through pharmacy dispensing technologies and patient data frameworks. The board will be chaired by Europe’s foremost medical cannabis expert Professor Mike Barnes, and will include some of the regions leading innovators in cannabinoid science, health tech and clinical practice. 

LYPHE has said that work will now begin on building rigorous datasets using the largest pool of active patients in the UK to unearth patterns on tolerability and effectiveness that can assist LYPHE Group’s doctors in optimising clinical pathways.

Professor Barnes: “Since medical cannabis was rescheduled in the UK, LYPHE has been at the forefront of the movement while always focused on the development of ventures to give patients access to a medicine they so desperately need. I’m honoured to be selected as Chair of the Medical Advisory Board at this pinnacle stage of growth and delighted to be sharing the table with such a talented group of experts in their relevant fields.”

Cannabis across Europe

LYPHE Group’s new Medical Advisory Board will provide oversight to the business in the ongoing development of proprietary softwares that will set a blueprint for medical cannabis dispensing management across Europe.

The advisors forming the board include:

Professor Mike Barnes, consultant neurologist and chair of the Medical Cannabis Clinicians Society who has been the industry leader for change in the UK and further afield. He has trained almost all prescribing doctors in the UK.

Dr Karen Wright, senior lecturer in biomedicine and principal of Grizedale College at Lancaster University. Dr Wright’s research began with inflammatory cell signalling in the gut, which then progressed to the cellular and molecular mechanisms of the endocannabinoid system in gastrointestinal diseases. Her publications include topics ranging from cannabinoid signalling, wound healing and mucosal barrier function. She collaborates with clinicians, industry and academics to work towards realising the therapeutic potential of cannabis-based medicines.

Farid Poonja, previous head of healthcare product and engineering at Walgreens Boots Alliance and a thought leader in the healthtech space. Poonja has delivered large scale digital healthcare transformation projects and platforms in the UK, Europe and USA, including Boots Health Hub and the NHS Electronic Prescription Service. Across Europe he has overseen the development of various digital tools to support independent pharmacies.

Dr Sunny Nayee, pain consultant and medical director of The Medical Cannabis Clinics. Dr Nayee was trained at Cambridge University Medical School before receiving the Strategic Health Authorities Prize. Prescribing medical cannabis to his patients with great success since 2019, Dr Nayee treats well in excess of 1,000 patients today and is considered to be the leading prescriber of medical cannabis in the UK.

Chris Ashton, chief pharmacist at LYPHE Group with more than 20 years of experience in leading roles within the pharmaceutical industry for companies such as Sainsburys, Bullens and Clinigen. Chris is the leading UK pharmacist in the medical cannabis sector and has been instrumental in the supply of medical cannabis to the UK He also serves as superintendent pharmacist at LYPHE Group owned, cannabis dispensary, Dispensary Green.

[activecampaign form=31]

Related Posts

Related Posts


Related Posts

Related Posts

Recent Posts

Related Posts

Subscribe to our mailing list to receives daily updates!

We won’t spam you


Browse by Tags




© 2023 Prohibition Holdings Ltd. All Rights Reserved.


Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?